Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior

2021/05/09 by Briana K. Chen, Victor M. Luna, Margaret E. Shannon +6 · 8 citations
Medicine · Neuroscience · #Treatment of Major Depression #Tryptophan and brain disorders #Neurotransmitter Receptor Influence on Behavior

paper · doi:10.1016/j.biopsych.2021.04.024

Citations

• A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
• Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

Cited by

• NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry
• Pharmacological Characterization of [ 18 F]-FNM and Evaluation of NMDA Receptors Activation in a Rat Brain Injury Model. [europepmc]
• Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease. [europepmc]
• Targeting N -Methyl-d-Aspartate Receptors in Neurodegenerative Diseases. [europepmc]
• NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders. [europepmc]
• NMDA Receptors: Distribution, Role, and Insights into Neuropsychiatric Disorders. [europepmc]
• Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease. [europepmc]
• NMDA Receptor Mediated Mechanisms in the Post-Stroke Brain: From Physiology to Pathology [europepmc]